Merck Licenses NanoBio Technology

By

NanoBio Corporation today announced a licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of its nanoemulsion (NE) adjuvant technology.  Under the agreement, Merck receives exclusive rights to NanoBio’s NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and … Continued